Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Human HRAS Antikörper:
anti-Rat (Rattus) HRAS Antikörper:
anti-Mouse (Murine) HRAS Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Polyclonal HRAS Primary Antibody für IF, IHC (p) - ABIN392183
Ma, Liu, Wu, Terada: p66(Shc) restrains Ras hyperactivation and suppresses metastatic behavior. in Oncogene 2010
Show all 2 Pubmed References
Human Polyclonal HRAS Primary Antibody für ELISA, WB - ABIN561363
Ambrosini, Khanin, Carvajal, Schwartz: Overexpression of DDX43 mediates MEK inhibitor resistance through RAS Upregulation in uveal melanoma cells. in Molecular cancer therapeutics 2014
our identification of the novel interaction between Aurora A (zeige AURKA Antikörper) and H-Ras as a mechanism by which Aurora A (zeige AURKA Antikörper) can activate Ras-MAPK (zeige MAPK1 Antikörper) signaling opens the way for studies into perturbation of the Aurora A (zeige AURKA Antikörper)/H-Ras interaction and the effect on Ras-MAPK (zeige MAPK1 Antikörper) signaling.
Peroxiredoxin I (Prx (zeige PRDX6 Antikörper) I) increased in tumors of hepatocellular carcinoma (HCC (zeige FAM126A Antikörper)) patients that aligned with overexpression of oncogenic H-ras.
Familial alcohol dependence was associated with hypomethylation of CpG sites in the HRAS promoter region.
Suppression of MEK/ERK pathway in senescent cells provides a new strategy for elimination of Ras-expressing cells.
ESR1 inhibits senescence-like phenotype and facilitates transformation induced by oncogenic ras in human mammary epithelial cells
Data show that STK38 supports Ras-driven transformation through promoting detachment-induced autophagy.
Data indicate acquired KRAS, NRAS (zeige NRAS Antikörper) or HRAS mutations in more than one third of patients after cetuximab exposure.
HRAS mutations were more common in epithelial-myoepithelial carcinomas (EMCAs) with intact PLAG1 (zeige PLAG1 Antikörper) and HMGA2. Most EMCAs arose ex pleomorphic adenoma (PA)and the genetic profile of EMCA varies with the absence or presence of preexisting PA and its cytogenetic signature. Progression to higher grade EMCA with intact PLAG1 (zeige PLAG1 Antikörper) and HMGA2 correlates with the presence of TP53 (zeige TP53 Antikörper), FBXW7 (zeige FBXW7 Antikörper) mutations, or SMARCB1 (zeige SMARCB1 Antikörper) deletion.
Analysis of HRAS mutations and their respiratory phenotype revealed that the common p.Gly12Ser mutation is more often associated with transient respiratory distress and other respiratory diagnoses.
we found that H-Ras proteins and particularly the G12V and G13D variants are significantly more flexible than their K-Ras counterparts.while most of the simulated proteins sampled the effector-interacting state 2 conformational state, G12V and G13D H-Ras adopted an open switch state 1 conformation that is defective in effector interaction
Kita driven expression of oncogenic HRAS leads to early onset and highly penetrant melanoma in zebrafish
Data demonstrate that H-Ras activation is important in the activation of the specific signaling events leading to the accelerated retinal capillary cell apoptosis in hyperglycemic conditions.
Activation of H-Ras and its downstream signaling pathway in the retina and its vasculature could be under the control of superoxide, and H-Ras activation in diabetes can be prevented by inhibiting superoxide accumulation.
Thrombospondin 1 (zeige THBS1 Antikörper), fibronectin (zeige FN1 Antikörper), and vitronectin (zeige VTN Antikörper) are differentially dependent upon RAS, ERK1/2, and p38 (zeige MAPK14 Antikörper) for induction of vascular smooth muscle cell chemotaxis.
Loss of wild-type Hras promotes the earliest stages of pancreatic tumorigenesis, and moreover results in more rapid progression of the disease. As such, mechanisms leading to activation of wild-type Ras proteins, including but not limited to redox-dependent reactions, may influence the development of pancreatic cancer.
High HRAS expression is associated with hepatocarcinogenesis.
p21 (zeige D4S234E Antikörper)-associated inhibition of early-stage malignant progression and the intense expression in papilloma outgrowths, identifies a novel, significant antagonism between p21 (zeige D4S234E Antikörper) and ras(Ha)/ROCK2 (zeige ROCK2 Antikörper)/NF-kappaB (zeige NFKB1 Antikörper) signalling in skin carcinogenesis.these data show that ROCK2 (zeige ROCK2 Antikörper) activation induces malignancy in ras(Ha)-initiated/promoted papillomas in the context of p53 (zeige TP53 Antikörper) loss and novel NF-kappaB (zeige NFKB1 Antikörper) expression
this study shows that retinoic acid stabilizes HRas protein during neurogenesis.
we provide genetic evidence that the wild-type H-Ras and K-Ras proteins are bioequivalent in spite of their different structural and biological properties
loss of one allele of Hras increased the sensitivity of mice to this carcinogen, and this effect was further exacerbated by the loss of the second Hras allele. However, loss of one or both alleles of Nras (zeige NRAS Antikörper) failed to alter tumor burden, either in the absence or presence of Hras, after exposure to urethane.
H-ras isoform mediates protection against pressure overload-induced cardiac dysfunction in part through activation of AKT (zeige AKT1 Antikörper)/PI3K signaling pathway.
The long intergenic non-coding RNA CCR492 functions as a let-7 competitive endogenous RNA to de-repress c-Myc (zeige MYC Antikörper) expression and to promote cell transformation assisted by the constitutively active H-Ras.
these contrasting signatures precisely match those proposed to confer bias toward Hras(CAA61CTA) versus Braf (zeige BRAF Antikörper)(GTG636GAG) mutations in the original tumor sets. Our findings highlight a novel mechanism whereby exposure history acts through strand-biased mutagenesis to specify activation of preferred oncogenes
The abnormal expression of epidermal cytokeratins suggests that Ha-Ras and Bcl-2 (zeige BCL2 Antikörper) suppress the terminal differentiation and sustain the stem cell-like features in epidermal keratinocytes
This gene belongs to the Ras oncogene family, whose members are related to the transforming genes of mammalian sarcoma retroviruses. The products encoded by these genes function in signal transduction pathways. These proteins can bind GTP and GDP, and they have intrinsic GTPase activity. This protein undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Mutations in this gene cause Costello syndrome, a disease characterized by increased growth at the prenatal stage, growth deficiency at the postnatal stage, predisposition to tumor formation, mental retardation, skin and musculoskeletal abnormalities, distinctive facial appearance and cardiovascular abnormalities. Defects in this gene are implicated in a variety of cancers, including bladder cancer, follicular thyroid cancer, and oral squamous cell carcinoma. Multiple transcript variants, which encode different isoforms, have been identified for this gene.
GTP- and GDP-binding peptide B
, GTPase HRas
, Ha-Ras1 proto-oncoprotein
, Ras family small GTP binding protein H-Ras
, c-has/bas p21 protein
, c-ras-Ki-2 activated oncogene
, p19 H-RasIDX protein
, transformation gene: oncogene HAMSV
, transforming protein p21
, v-Ha-ras Harvey rat sarcoma viral oncogene homolog
, Transforming protein p21
, neuroblastoma ras oncogene
, v-Ha-ras Harvey rat sarcoma viral oncogene-like protein
, Harvey ras1 protein
, Harvey rat sarcoma viral (v-Ha-ras) oncogene homolog
, ras p21
, small G-protein H-Ras
, GTPase HRas (Transforming protein p21) (H-Ras-1) (c-H-ras)
, Harvey ras 1
, H-ras 1 protein
, c-Ha-ras p21 protein
, c-Ha-ras transgene
, transforming protein P21